Willing to follow diet counseling and maintain a stable low-fat diet
Must be on standard of care lipid and TG-lowering medications per local guidelines (unless documented as intolerant, or a treatment failure as determined by the Investigator)
You may not be if
Use of any hepatocyte-targeted small interfering ribonucleic acid (siRNA) that targets lipids and/or triglycerides within 365 days before Day 1, except inclisiran.
Use of any other hepatocyte targeted siRNA or antisense oligonucleotide molecule within 60 days or within 5 half-lives lives before day 1. Whichever is longer.
AP ≤ 4 weeks prior to Randomization/Day 1
Body mass index (BMI) \> 45 kg/m\^2
Any planned bariatric surgery or similar procedures to induce weight lost starting at consent through End of Study (EOS)
Planned coronary intervention (e.g. stent placement or heart bypass) during the study
History of arterial revascularization within 16 weeks of Screening
History of acute coronary syndrome event within 24 weeks of Screening
Recent atherosclerotic cardiovascular disease (ASCVD) event within 24 weeks of Screening
Recent unstable or symptomatic cardiac arrhythmia (including any associated medication changes) within 90 days of Screening. Individuals with stable well-controlled atrial arrhythmia will be allowed to participate in the study
History of pacemaker or automatic implantable cardioverter defibrillators implant within 30 days before Screening
New York Heart Association Class III-IV heart failure or last known ejection fraction of \< 30%
Current diagnosis of nephrotic syndrome
Chronic kidney disease, defined by an estimated glomerular filtration rate (eGFR) \< 20 mL/min/1.73 m\^2
Liver disease defined as cirrhosis or Child-Pugh Class B and C, or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2.5× Upper Limit of Normal (ULN) at Screening
Clareo Health | Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
